AKBA

Akebia Therapeutics Inc. (AKBA) | Rumor.io

Akebia Therapeutics

AKBA

Attention (50-day avg)0.01%

Attention rank (50-day avg)#535

Bullish sentiment (50-day avg)62%

Price to earnings ratio-45

Market capitalization247.5M

Earnings per share-0.12

Dividend yield (TTM)—

Revenue (annual)236.2M

Net income (annual)-5.3M

Social

What share of all stock conversation is about AKBA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% +0	0.01% 0	0.01% 0	0.01% -0.05

Sep 29

Akebia Therapeutics, Inc. ($AKBA) is advancing the science behind its commercial product Vafseo, an oral therapy for anemia due to chronic kidney disease.
The company's pipeline includes investigational therapies for rare kidney diseases with significant unmet need.
Analysts and investors are optimistic about the stock's potential, with some predicting a price increase to $1 or $30 by 2026 Q4.

Generated by AI

Sentiment

Of the messages about AKBA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	35.42% +4.38	39.64% -23.21	61.6% +5.15	69.16% -14.84
Bearish	64.58% -4.38	60.36% +23.21	38.4% -5.15	30.84% +14.84

Bullish· Aug 10

Akebia Therapeutics, Inc. has a strong pipeline with multiple indications, including AAV anca-associated Vasculitis, which has a real shot at getting fast-tracked and being the company's first indication to market.
The company's product, Vafseo, has already captured one-third of the eligible TAM of DD anemic stable on dialysis with TDAPA market at USRC, DCI, and IRC, and it's likely that Davita and Fresenius will follow, potentially leading to significant cost savings for the company.
Akebia's stock price is attractive to both retail and institutional investors, with an average cost basis for all shares holding at $1.07, and the company's retail-heavy shareholder base can cause this kind of response after disappointing earnings reactions, but may also lead to a rebound.

Bearish· Aug 28

The company's valuation is overextended, with some arguing it's worth $250-350M despite less than $180M in revenue this year and next.
The stock has lost 97% of its value since inception, and management's dilution policies have contributed to the decline.
Heavy shorting and technical breakdowns have led to a significant decline in the company's value, with some market players taking advantage of the situation.

Generated by AI

Topics

Of the messages about AKBA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	80%	93.62%	86.49%	46.63%
Earnings	0%	0%	0%	20.83%
Technical Analysis	20%	6.38%	13.06%	23.5%
Analysts	0%	0%	0.45%	6.34%
Controversies	0%	0%	0%	0.29%
Macro	0%	0%	0%	2.41%

Earnings· Feb 26

Akebia Therapeutics reported Q4 2025 earnings, with revenue of $57.62M, a 23.92% increase YoY, and a GAAP EPS of -$0.05, a 50% improvement YoY.
The company expects significant Vafseo revenue growth in 2026, while Auryxia revenues are anticipated to decrease due to generic competition.
Akebia projects existing cash resources will fund its operating plan for at least two years, and Q1 2026 is expected to show significant growth in Vafseo.

Analysts· Mar 31

Akebia Therapeutics ($AKBA) was downgraded to Neutral by multiple analysts, including Mizuho, Piper Sandler, HC Wainwright, and BTIG Research.
The downgrades were due to various reasons, including a complete response letter from the FDA for the company's NDA for vadadustat to treat anemia in patients with chronic kidney disease.
Analyst sentiment for $AKBA is mildly confident, with a buy consensus of 80% among 13 analysts.

Announcements· Feb 26

Akebia Therapeutics' Vafseo is showing improved commercial trends in early 2026, with patient access to the therapy standing at 290,000 patients.
The company's Q4 2025 net product revenue was $54.3M, with full-year revenue of $227.3M, a 49% year-over-year increase.
Akebia Therapeutics is expecting significant revenue growth for Vafseo in 2026, driven by expanded access to therapy at dialysis organizations, new patient starts, and improved adherence rates.

Controversies· Mar 17

Akebia Therapeutics, Inc. (AKBA) is facing a class action lawsuit following a significant price decline in September 2020.
Investors are suing AKBA, alleging that the company will have a "windfall of profits" from its drug, which is cited as a reason for the timing of the lawsuits.
A class action lawsuit deadline has been announced for March 29, and investors are encouraged to secure counsel before the deadline.

Technical Analysis· Mar 28

$AKBA has strong support at $1.80, which was previously resistance for 7 months.
The stock is in a bear flag pattern on a downtrend, but has a chance for a triple bottom.
Above its VWAP and RSI is oversold, indicating room for the stock to run, with potential pullback points at $1.75-$1.85.

Generated by AI

Community

Of the messages about AKBA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	96.92%	93.48%	97.11%	95.51%
Newcomers	3.08%	6.52%	2.89%	4.49%

Regulars· Sep 29

Akebia Therapeutics' commercial product Vafseo, an oral therapy for anemia due to chronic kidney disease, is advancing Nobel Prize-winning science behind hypoxia-inducible factor prolyl hydroxylase inhibitors.
The stock is being shorted due to concerns that access to life-saving and life-bettering drugs is being stalled and thwarted, harming and killing chronically ill patients.
John Butler's leadership of Akebia Therapeutics is being questioned, with some investors expressing distrust and accusing him of stealing their money and making empty promises of shareholder value.

Newcomers· Aug 6

Newcomers to the Akebia Therapeutics (AKBA) stock are focused on the company's ability to outmaneuver GlaxoSmithKline (GSK) in the dialysis market, particularly through Akebia's alignment with Large Dialysis Organizations (LDOs) like DaVita.
The slow rollout of DaVita's adoption of Akebia's new drug is attributed to the centers' strategy to suppress adoption volumes early on to use as leverage to force the manufacturer into a massive price cut later.
The VOICE study is seen as a major long-term catalyst for AKBA and Vafseo, as it evaluates real patient outcomes and demonstrates the clinical and economic value of Vafseo in comparison to ESA therapies.

Generated by AI

Open-label Phase 2 trial evaluating ebribafusp for the treatment of IgA nephropathy, lupus nephritis and C3 glomerulopathy Initial data is expected in 2027 WALTHAM, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the first patient has been dosed in its Phase 2 basket trial evaluating ebribafusp for the treatment of rare complement-mediat

16d agoYahoo Finance Singapore

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 8,400 shares of Akebia’s common stock on August 31, 2026. The options were granted as an inducement material to the employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(

28d agoYahoo Finance UK

Akebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in Boston

CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer and Erik Ostrowski, Chief Financial and Chief Business Officer, will participate in one-on-one meetings at the Wells Fargo Healthcare Conference, which will take place in Boston, September 8 – 10, 2026. During meetings, management will disc

29d agoYahoo! Finance Canada

H.C. Wainwright reiterates Buy on Akebia stock, $6 target

1mo agoInvesting.com

Akebia Therapeutics Inc (AKBA) (Q2 2026) Earnings Call Highlights: Vafseo Surges 60% as VOICE ...

1mo agoYahoo Finance

Also Discussed

Investors talking about AKBA also mention

#	Name	Attention
1	FGEN - FibroGen, Inc.	——
2	OCFT - OneConnect Financial Technology Co., Ltd.	——
3	Seres Therapeutics Inc.MCRB	0%0
4	Ardelyx IncARDX	0.01%+0.01
5	Cyclerion Therapeutics IncCYCN	0%new
6	BLUE - bluebird bio, Inc.	——
7	CTIC - CTI BioPharma Corp.	——
8	Fresenius Medical Care AG - Depositary ReceiptFMS	0%new
9	LMNL - Liminal BioSciences Inc.	——
10	BioCryst Pharmaceuticals, Inc.BCRX	0.01%+0.01

Akebia Therapeutics Inc.

Healthcare
Drug Manufacturers - Specialty & Generic

Akebia Therapeutics Inc. is a biopharmaceutical company focused on developing and commercializing therapies for people living with kidney disease. Its current product portfolio centers on treatments for chronic kidney disease-related complications, including anemia management and phosphorus control, supported by a nephrology-focused commercial organization. The company’s marketed medicines are used in renal care settings and address medical needs across dialysis and non-dialysis patient populations. Akebia also maintains a development pipeline built around hypoxia-inducible factor biology, which underpins its research in kidney disease and related metabolic disorders. Headquartered in Cambridge, Massachusetts, Akebia Therapeutics Inc. serves as a specialized player in the renal therapeutics market, combining commercial products, development-stage assets, and collaboration-based programs to support treatment options in nephrology.

Website

Location

245 First Street

Cambridge, MA, 02142

United States

Social

What share of all stock conversation is about AKBA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% +0	0.01% 0	0.01% 0	0.01% -0.05

Sep 29

Akebia Therapeutics, Inc. ($AKBA) is advancing the science behind its commercial product Vafseo, an oral therapy for anemia due to chronic kidney disease.
The company's pipeline includes investigational therapies for rare kidney diseases with significant unmet need.
Analysts and investors are optimistic about the stock's potential, with some predicting a price increase to $1 or $30 by 2026 Q4.

Generated by AI

Sentiment

Of the messages about AKBA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	35.42% +4.38	39.64% -23.21	61.6% +5.15	69.16% -14.84
Bearish	64.58% -4.38	60.36% +23.21	38.4% -5.15	30.84% +14.84

Bullish· Aug 10

Akebia Therapeutics, Inc. has a strong pipeline with multiple indications, including AAV anca-associated Vasculitis, which has a real shot at getting fast-tracked and being the company's first indication to market.
The company's product, Vafseo, has already captured one-third of the eligible TAM of DD anemic stable on dialysis with TDAPA market at USRC, DCI, and IRC, and it's likely that Davita and Fresenius will follow, potentially leading to significant cost savings for the company.
Akebia's stock price is attractive to both retail and institutional investors, with an average cost basis for all shares holding at $1.07, and the company's retail-heavy shareholder base can cause this kind of response after disappointing earnings reactions, but may also lead to a rebound.

Bearish· Aug 28

The company's valuation is overextended, with some arguing it's worth $250-350M despite less than $180M in revenue this year and next.
The stock has lost 97% of its value since inception, and management's dilution policies have contributed to the decline.
Heavy shorting and technical breakdowns have led to a significant decline in the company's value, with some market players taking advantage of the situation.

Generated by AI

Topics

Of the messages about AKBA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	80%	93.62%	86.49%	46.63%
Earnings	0%	0%	0%	20.83%
Technical Analysis	20%	6.38%	13.06%	23.5%
Analysts	0%	0%	0.45%	6.34%
Controversies	0%	0%	0%	0.29%
Macro	0%	0%	0%	2.41%

Earnings· Feb 26

Akebia Therapeutics reported Q4 2025 earnings, with revenue of $57.62M, a 23.92% increase YoY, and a GAAP EPS of -$0.05, a 50% improvement YoY.
The company expects significant Vafseo revenue growth in 2026, while Auryxia revenues are anticipated to decrease due to generic competition.
Akebia projects existing cash resources will fund its operating plan for at least two years, and Q1 2026 is expected to show significant growth in Vafseo.

Analysts· Mar 31

Akebia Therapeutics ($AKBA) was downgraded to Neutral by multiple analysts, including Mizuho, Piper Sandler, HC Wainwright, and BTIG Research.
The downgrades were due to various reasons, including a complete response letter from the FDA for the company's NDA for vadadustat to treat anemia in patients with chronic kidney disease.
Analyst sentiment for $AKBA is mildly confident, with a buy consensus of 80% among 13 analysts.

Announcements· Feb 26

Akebia Therapeutics' Vafseo is showing improved commercial trends in early 2026, with patient access to the therapy standing at 290,000 patients.
The company's Q4 2025 net product revenue was $54.3M, with full-year revenue of $227.3M, a 49% year-over-year increase.
Akebia Therapeutics is expecting significant revenue growth for Vafseo in 2026, driven by expanded access to therapy at dialysis organizations, new patient starts, and improved adherence rates.

Controversies· Mar 17

Akebia Therapeutics, Inc. (AKBA) is facing a class action lawsuit following a significant price decline in September 2020.
Investors are suing AKBA, alleging that the company will have a "windfall of profits" from its drug, which is cited as a reason for the timing of the lawsuits.
A class action lawsuit deadline has been announced for March 29, and investors are encouraged to secure counsel before the deadline.

Technical Analysis· Mar 28

$AKBA has strong support at $1.80, which was previously resistance for 7 months.
The stock is in a bear flag pattern on a downtrend, but has a chance for a triple bottom.
Above its VWAP and RSI is oversold, indicating room for the stock to run, with potential pullback points at $1.75-$1.85.

Generated by AI

Community

Of the messages about AKBA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	96.92%	93.48%	97.11%	95.51%
Newcomers	3.08%	6.52%	2.89%	4.49%

Regulars· Sep 29

Akebia Therapeutics' commercial product Vafseo, an oral therapy for anemia due to chronic kidney disease, is advancing Nobel Prize-winning science behind hypoxia-inducible factor prolyl hydroxylase inhibitors.
The stock is being shorted due to concerns that access to life-saving and life-bettering drugs is being stalled and thwarted, harming and killing chronically ill patients.
John Butler's leadership of Akebia Therapeutics is being questioned, with some investors expressing distrust and accusing him of stealing their money and making empty promises of shareholder value.

Newcomers· Aug 6

Newcomers to the Akebia Therapeutics (AKBA) stock are focused on the company's ability to outmaneuver GlaxoSmithKline (GSK) in the dialysis market, particularly through Akebia's alignment with Large Dialysis Organizations (LDOs) like DaVita.
The slow rollout of DaVita's adoption of Akebia's new drug is attributed to the centers' strategy to suppress adoption volumes early on to use as leverage to force the manufacturer into a massive price cut later.
The VOICE study is seen as a major long-term catalyst for AKBA and Vafseo, as it evaluates real patient outcomes and demonstrates the clinical and economic value of Vafseo in comparison to ESA therapies.

Generated by AI

Akebia Therapeutics

Social

Sep 29

Bullish· Aug 10

Bearish· Aug 28

Earnings· Feb 26

Analysts· Mar 31

Announcements· Feb 26

Controversies· Mar 17

Technical Analysis· Mar 28

Regulars· Sep 29

Newcomers· Aug 6

Akebia doses first patient in Phase 2 kidney disease trial

Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in Boston

H.C. Wainwright reiterates Buy on Akebia stock, $6 target

Akebia Therapeutics Inc (AKBA) (Q2 2026) Earnings Call Highlights: Vafseo Surges 60% as VOICE ...

Also Discussed

Akebia Therapeutics Inc.

Company Information

Location

Akebia doses first patient in Phase 2 kidney disease trial

Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in Boston

H.C. Wainwright reiterates Buy on Akebia stock, $6 target

Akebia Therapeutics Inc (AKBA) (Q2 2026) Earnings Call Highlights: Vafseo Surges 60% as VOICE ...

Also Discussed

Social

Sep 29

Bullish· Aug 10

Bearish· Aug 28

Earnings· Feb 26

Analysts· Mar 31

Announcements· Feb 26

Controversies· Mar 17

Technical Analysis· Mar 28

Regulars· Sep 29

Newcomers· Aug 6